Label: KARBINAL ER- carbinoxamine maleate suspension, extended release

  • NDC Code(s): 23594-101-01, 23594-101-05
  • Packager: Zylera Pharmaceuticals, LLC
  • Category: HUMAN PRESCRIPTION DRUG LABEL

Drug Label Information

Updated August 20, 2018

If you are a healthcare professional or from the pharmaceutical industry please visit this version.

  • HIGHLIGHTS OF PRESCRIBING INFORMATION
    These highlights do not include all the information needed to use KARBINAL ® ER safely and effectively. See full prescribing information for KARBINAL ® ER.

    Karbinal ® ER (carbinoxamine maleate) extended-release oral suspension
    Initial U.S. Approval: 1953

    INDICATIONS AND USAGE

    Karbinal ER (carbinoxamine maleate) Extended-release Oral Suspension is an H1 receptor antagonist indicated for the symptomatic treatment of:

    • Seasonal and perennial allergic rhinitis (1)
    • Vasomotor rhinitis (1)
    • Allergic conjunctivitis due to inhalant allergens and foods (1)
    • Mild, uncomplicated allergic skin manifestations of urticaria and angioedema (1)
    • Dermatographism (1)
    • As therapy for anaphylactic reactions adjunctive to epinephrine and other standard measures after the acute manifestations have been controlled (1)
    • Amelioration of the severity of allergic reactions to blood or plasma (1)

    DOSAGE AND ADMINISTRATION

    Adults and Adolescents 12 years of age and older (2):

      7.5 mL to 20 mL (6 to 16 mg) every 12 hours

    Children 2-11 years of age (approximately 0.2 to 0.4 mg/kg/day) (2):

      2 to 3 years – 3.75 mL to 5 mL (3 to 4 mg) every 12 hours

      4 to 5 years – 3.75 mL to 10 mL (3 to 8 mg) every 12 hours

      6 to 11 years – 7.5 mL to 15 mL (6 to 12 mg) every 12 hours

    DOSAGE FORMS AND STRENGTHS

    Extended-Release Oral Suspension: 4 mg carbinoxamine maleate per 5 mL (3)

    CONTRAINDICATIONS

    • Children younger than 2 years of age (4.1)
    • Nursing mothers (4.2)
    • Patients with known hypersensitivity to the drug or any of the inactive ingredients (4.3 and 5.3)
    • Monoamine oxidase inhibitors (MAOI) (4.4 and 7)

    WARNINGS AND PRECAUTIONS

    • Activities requiring mental alertness: Avoid engaging in hazardous tasks requiring complete mental alertness such as driving or operating machinery. (5.2)
    • Anticholinergic actions: Use with caution in patients with increased intraocular pressure, narrow angle glaucoma, hyperthyroidism, cardiovascular disease, hypertension, stenosing peptic ulcer, symptomatic prostatic hypertrophy, bladder neck obstruction, pyloroduodenal obstruction. (5.3)
    • Contains sodium metabisulfite, a sulfite that may cause anaphylaxis including life-threatening or less severe asthmatic episodes in susceptible individuals. (5.4)

    ADVERSE REACTIONS

    Most common adverse reactions are: sedation, sleepiness, dizziness, disturbed coordination, epigastric distress, and thickening of bronchial secretions. (6)

    To report SUSPECTED ADVERSE REACTIONS, contact Cerecor, Inc., at 1-866-416-9637 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

    DRUG INTERACTIONS

    • Monoamine oxidase inhibitors (MAOIs): Prolong and intensify the anticholinergic (drying) effects. (4.4 and 7)
    • Alcohol and CNS depressants (hypnotics, sedatives, tranquilizers, etc.): Avoid concomitant use due to additive adverse effects. (7)

    USE IN SPECIFIC POPULATIONS

    • Because of the higher risk of serious adverse reactions with use of carbinoxamine maleate in infants, Karbinal ER is contraindicated in nursing women. (8.3)
    • Contraindicated in children younger than 2 years of age. (8.4)
    • May cause sedation or excitation in young children. (8.4)
    • May cause dizziness, sedation, and hypotension in elderly patients. Start elderly patients on lower doses and observe closely for confusion and over-sedation. (8.5)

    See 17 for PATIENT COUNSELING INFORMATION.

    Revised: 8/2018

    Close
  • FULL PRESCRIBING INFORMATION: CONTENTS*
  • 1 INDICATIONS AND USAGE

    Karbinal ER Extended-release Oral Suspension is an H1 receptor antagonist indicated for the symptomatic treatment of:

    • Seasonal and perennial allergic rhinitis
    • Vasomotor rhinitis
    • Allergic conjunctivitis due to inhalant allergens and foods
    • Mild, uncomplicated allergic skin manifestations of urticaria and angioedema
    • Dermatographism
    • As therapy for anaphylactic reactions adjunctive to epinephrine and other standard measures after the acute manifestations have been controlled
    • Amelioration of the severity of allergic reactions to blood or plasma
    Close
  • 2 DOSAGE AND ADMINISTRATION

    The dosage of Karbinal ER should be individualized based on the severity of the condition and the response of the patient. Start with lower doses and increase as needed and tolerated.

    Administer Karbinal ER by the oral route only. Measure Karbinal ER with an accurate milliliter measuring device. A household teaspoon is not an accurate measuring device and could lead to overdosage. A pharmacist can provide an appropriate measuring device and can provide instructions for measuring the correct dose. [see Warnings and Precautions (5.5)]

    Adults and Adolescents 12 years of age and older:

      7.5 mL to 20 mL (6 to 16 mg) every 12 hours

    Children 2 to 11 years of age (approximately 0.2 to 0.4 mg/kg/day):

      2 to 3 years: 3.75 mL to 5 mL (3 to 4 mg) every 12 hours

      4 to 5 years: 3.75 mL to 10 mL (3 to 8 mg) every 12 hours

      6 to 11 years: 7.5 mL to 15 mL (6 to 12 mg) every 12 hours

    Close
  • 3 DOSAGE FORMS AND STRENGTHS

    Extended-release oral suspension containing 4 mg carbinoxamine maleate per 5 mL

    Close
  • 4 CONTRAINDICATIONS

    4.1 Children less than 2 years of age

    Karbinal ER is contraindicated in children younger than 2 years of age because deaths have been reported in this age group [see Warnings and Precautions (5.1)].

    4.2 Nursing Mothers

    Karbinal ER is contraindicated in nursing mothers because of the risk of mortality in infants given carbinoxamine-containing products [see Use in Specific Populations (8.3)].

    4.3 Hypersensitivity

    Karbinal ER is contraindicated in patients who are hypersensitive to carbinoxamine maleate or any of the inactive ingredients in Karbinal ER [see Warnings and Precautions (5.4)].

    4.4 Monoamine oxidase inhibitors

    Karbinal ER is contraindicated in patients who are taking monoamine oxidase inhibitors (MAOI) [see Drug Interactions (7)].

    Close
  • 5 WARNINGS AND PRECAUTIONS

    5.1 Pediatric Mortality

    Deaths have been reported in children less than 2 years of age who were taking carbinoxamine-containing drug products; therefore, Karbinal ER is contraindicated in children younger than 2 years of age.

    5.2 Activities Requiring Mental Alertness

    Karbinal ER may produce marked drowsiness and impair the mental or physical abilities required for the performance of potentially hazardous tasks such as driving a car or operating machinery. Advise patients to avoid engaging in hazardous tasks requiring mental alertness and motor coordination after ingestion of Karbinal ER. Avoid concurrent use of Karbinal ER with alcohol or other central nervous system depressants because additional impairment of central nervous system performance may occur.

    5.3 Concomitant Medical Conditions

    Karbinal ER has anticholinergic (atropine-like) properties and, therefore, should be used with caution in patients with: increased intraocular pressure, narrow angle glaucoma, hyperthyroidism, cardiovascular disease, hypertension, stenosing peptic ulcer, symptomatic prostatic hypertrophy, bladder neck obstruction, or pyloroduodenal obstruction.

    5.4 Allergic Reactions due to Sulfites

    Karbinal ER contains sodium metabisulfite, a sulfite that may cause allergic-type reactions, including anaphylaxis and life-threatening or less severe asthmatic episodes, in susceptible individuals. The overall prevalence of sulfite sensitivity in the general population is unknown and probably low. Sulfite sensitivity is seen more frequently in asthmatic than in nonasthmatic individuals.

    5.5 Dosing

    Advise patients to measure Karbinal ER with an accurate milliliter measuring device. A household teaspoon is not an accurate measuring device and could lead to overdosage. A pharmacist can recommend an appropriate measuring device and can provide instructions for measuring the correct dose.

    Close
  • 6 ADVERSE REACTIONS

    Use of Karbinal ER may result in decreased mental alertness with impaired mental or physical abilities [see Warnings and Precautions (5.2)].

    The most frequent adverse reactions include: sedation, sleepiness, dizziness, disturbed coordination, epigastric distress, and thickening of bronchial secretions. In clinical use, younger children and older adults may be particularly sensitive to adverse reactions [see Pediatric Use (8.4) and Geriatric Use (8.5)].

    The following adverse reactions, listed by body system, have been identified in case reports and during the use of carbinoxamine in observational studies. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

    Body as a Whole: Urticaria, drug rash, anaphylactic shock, photosensitivity, excessive perspiration, chills, dryness of mouth, nose and throat.

    Cardiovascular: Hypotension, headache, palpitations, tachycardia, extrasystoles.

    Central Nervous System: Fatigue, confusion, restlessness, excitation, nervousness, tremor, irritability, insomnia, euphoria, paresthesia, blurred vision, diplopia, vertigo, tinnitus, acute labyrinthitis, hysteria, neuritis, convulsions.

    Gastrointestinal: Anorexia, nausea, vomiting, diarrhea, constipation.

    Hematologic: Hemolytic anemia, thrombocytopenia, agranulocytosis.

    Laboratory: Increase in uric acid levels.

    Respiratory: Tightness of chest and wheezing, nasal stuffiness.

    Urogenital: Urinary frequency, difficult urination, urinary retention, early menses.

    Close
  • 7 DRUG INTERACTIONS

    Use of Karbinal ER is contraindicated in patients who are taking monoamine oxidase inhibitors (MAOIs), which prolong and intensify the anticholinergic (drying) effects of antihistamines.

    Avoid use of Karbinal ER with alcohol and other CNS depressants (hypnotics, sedatives, tranquilizers, etc.) due to additive effects.

    Close
  • 8 USE IN SPECIFIC POPULATIONS

    8.1 Pregnancy

    Pregnancy Category C. Animal reproductive studies have not been conducted with carbinoxamine maleate. It is also not known whether Karbinal ER can cause fetal harm when administered to a pregnant woman or can affect reproductive capacity. Karbinal ER should be given to a pregnant woman only if clearly needed.

    8.2 Labor and Delivery

    The effect of Karbinal ER on labor and delivery is not known.

    8.3 Nursing Mothers

    Because of the risk of mortality in infants given carbinoxamine-containing drugs, use of Karbinal ER is contraindicated in nursing mothers.

    8.4 Pediatric Use

    Deaths have been reported in children younger than 2 years of age who were taking carbinoxamine-containing drug products. Therefore, Karbinal ER is contraindicated in children younger than 2 years of age and in nursing mothers. Carbinoxamine may diminish mental alertness or produce sedation in children. Paradoxical reactions with excitation are more likely in younger children.

    8.5 Geriatric Use

    Karbinal ER may cause dizziness, hypotension, confusion, or over-sedation in the elderly. Start elderly patients on lower doses and observe closely.

    Close
  • 10. OVERDOSAGE

    Overdosage with carbinoxamine may cause central nervous system depression or stimulation, hallucinations, convulsions, and death. Atropine-like signs and symptoms – dry mouth; fixed, dilated pupils; flushing; and gastrointestinal symptoms may also occur.

    The treatment of overdosage consists of discontinuation of Karbinal ER and institution of symptomatic and supportive therapy. Vital signs (including respiration, pulse, blood pressure, and temperature) and EKG should be monitored. Induction of vomiting is not recommended. Activated charcoal should be given and gastric lavage should be considered after ingestion of a potentially life-threatening amount of drug. In the presence of severe anticholinergic effects, physostigmine may be useful. Vasopressors may be used to treat hypotension.

    Close
  • 11. DESCRIPTION

    Each 5 mL of Karbinal ER Extended-release Oral Suspension contains carbinoxamine complexed with polistirex equivalent to 4 mg carbinoxamine maleate and the following inactive ingredients: citric acid anhydrous, strawberry-banana flavor, glycerin, high fructose corn syrup, methylparaben, modified food starch, polysorbate 80, polyvinyl acetate, povidone, propylparaben, purified water, sodium metabisulfite, sodium polystyrene sulfonate, sucrose, triacetin, and xanthan gum.

    Carbinoxamine maleate is freely soluble in water. The chemical name is 2-[(4-chlorophenyl)-2-pyridinylmethoxy]-N, N-dimethylethanamine (Z)-2-butenedioate (1:1), which has the following structure:

    Chemical Structure

    C16H19ClN2O∙C4H4O4                            MW = 406.86

    The drug-polistirex complex is formed with the active ingredient (carbinoxamine maleate, USP) and sodium polystyrene sulfonate, USP, which has the following structure:

    Chemical Structure
    Close
  • 12. CLINICAL PHARMACOLOGY

    12.1 Mechanism of Action

    Carbinoxamine is an H1 receptor antagonist (antihistamine) that exhibits anticholinergic (drying) and sedative properties.

    Antihistamines compete with histamine for receptor sites on effector cells.

    12.3 Pharmacokinetics

    Karbinal ER after single-dose administration of 16 mg was bioequivalent to the reference carbinoxamine immediate-release oral solution after the administration of two doses of 8 mg six hours apart under fasting conditions. The carbinoxamine mean (SD) peak plasma concentration (Cmax) was 28.7 (5.3) ng/mL at 6.7 hours after Karbinal ER administration. The plasma half-life of carbinoxamine was 17.0 hours. There was no effect of food on the pharmacokinetic parameters.

    Karbinal ER after multiple-dose administration of 16 mg every 12 hours for 8 days was bioequivalent to the reference carbinoxamine immediate-release oral solution after multiple-dose administration of 8 mg every 6 hours. The mean (SD) steady-state Cmax was 72.9 (24.4) ng/mL at 5.6 hours after Karbinal ER administration. Carbinoxamine mean (SD) minimum plasma concentration at steady-state was 51.8 (20.3) ng/mL.

    Close
  • 13. NONCLINICAL TOXICOLOGY

    13.1. Carcinogenesis, Mutagenesis, Impairment of Fertility

    No long-term studies in animals have been performed to determine the possible effects of carbinoxamine on carcinogenesis, mutagenesis, and fertility.

    Close
  • 14. CLINICAL STUDIES

    The efficacy and safety of Karbinal ER is based on demonstration of bioequivalence to the immediate-release reference product [see Pharmacokinetics (12.3)].

    Close
  • 16. HOW SUPPLIED/STORAGE AND HANDLING

    Karbinal ER contains 4 mg carbinoxamine maleate per 5 mL. It is a light beige to tan viscous suspension with strawberry-banana flavor and is supplied as follows:

    NDC 23594-101-05 Bottles of 16 fl oz (480 mL)
    NDC 23594-101-01 Bottles of 1 fl oz (30 mL) Physician Samples

    Store at 25°C (77°F); excursions permitted from 15° to 30°C (59° to 86°F). [See USP Controlled Room Temperature.]

    Dispense in tight, light-resistant container with child-resistant closure.

    Close
  • 17. PATIENT COUNSELING INFORMATION

    17.1. Dosing

    Advise patients to measure Karbinal ER with an accurate milliliter measuring device. A household teaspoon is not an accurate measuring device and could lead to overdosage. [see Dosage and Administration (2)].

    17.2. Activities Requiring Mental Alertness

    Advise patients to use caution when driving a motor vehicle or operating machinery. Karbinal ER may produce marked drowsiness and impair the mental or physical abilities required for the performance of potentially hazardous tasks such as driving a car or operating machinery [see Warnings and Precautions (5.2)].

    17.3. Alcohol, Sedatives, and Tranquilizers

    Advise patients to avoid the use of alcoholic beverages, sedatives, and tranquilizers while taking Karbinal ER because additional reduction in mental alertness may occur [see Warnings and Precautions (5.2) and Drug Interactions (7)].

    17.4. MAOIs

    Advise patients to not use MAOIs while taking Karbinal ER. MAOIs may prolong and intensify the anticholinergic (drying) effects [see Contraindications (4.4) and Drug Interactions (7)].

    Close
  • SPL UNCLASSIFIED SECTION

    Manufactured by:
    Tris Pharma, Inc.
    Monmouth Junction, NJ 08852

    Distributed by:

    Cerecor logo

    Cerecor, Inc.
    Research Triangle Park, NC 27713
    www.cerecor.com

    LB8056
    Rev 04
    08/2018

    Close
  • PRINCIPAL DISPLAY PANEL

    PRINCIPAL DISPLAY PANEL - 480 mL Bottle Label

    NDC 23594-101-05

    Karbinal ER
    (carbinoxamine maleate)
    Extended-release
    Oral Suspension

    4 mg/5 ml

    Shake Well Before Use

    Dose every 12 hours

    Dispense with an accurate
    milliliter measuring device

    Strawberry Banana Flavored

    Rx only 16 fl oz. (480 mL)

    480 mL Bottle Label
    Close
  • INGREDIENTS AND APPEARANCE
    KARBINAL   ER
    carbinoxamine maleate suspension, extended release
    Product Information
    Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:23594-101
    Route of Administration ORAL
    Active Ingredient/Active Moiety
    Ingredient Name Basis of Strength Strength
    Carbinoxamine Maleate (UNII: 02O55696WH) (Carbinoxamine - UNII:982A7M02H5) Carbinoxamine Maleate 4 mg  in 5 mL
    Inactive Ingredients
    Ingredient Name Strength
    Water (UNII: 059QF0KO0R)  
    Polysorbate 80 (UNII: 6OZP39ZG8H)  
    Sodium Metabisulfite (UNII: 4VON5FNS3C)  
    Glycerin (UNII: PDC6A3C0OX)  
    Methylparaben (UNII: A2I8C7HI9T)  
    Propylparaben (UNII: Z8IX2SC1OH)  
    Xanthan Gum (UNII: TTV12P4NEE)  
    Anhydrous Citric Acid (UNII: XF417D3PSL)  
    High Fructose Corn Syrup (UNII: XY6UN3QB6S)  
    Sucrose (UNII: C151H8M554)  
    Povidones (UNII: FZ989GH94E)  
    Sodium Polystyrene Sulfonate (UNII: 1699G8679Z)  
    Triacetin (UNII: XHX3C3X673)  
    Product Characteristics
    Color      Score     
    Shape Size
    Flavor STRAWBERRY (Strawberry Banana) Imprint Code
    Contains     
    Packaging
    # Item Code Package Description Marketing Start Date Marketing End Date
    1 NDC:23594-101-05 480 mL in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product 01/03/2014
    2 NDC:23594-101-01 2 in 1 CARTON 01/03/2014
    2 30 mL in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product
    Marketing Information
    Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
    NDA NDA022556 01/03/2014
    Labeler - Zylera Pharmaceuticals, LLC (032546121)
    Close